Ingram Micro set to join S&P SmallCap 600 following Viatris-Pacira deal (INGM:NYSE)

Ingram Micro (INGM) will join the S&P SmallCap 600, replacing Pacira BioSciences (PCRX), effective November 17, 2026, according to S&P Dow Jones Indices. Pacira is being acquired by Viatris.

Ingram Micro (INGM) will replace Pacira BioSciences (PCRX) in the S&P SmallCap 600 on November 17, following Viatris' (VTRS) planned acquisition of Pacira. INGM shares rose 4% in extended trading.

S&P Dow Jones Indices announced Ingram Micro (INGM) will replace Pacira BioSciences (PCRX) in the S&P SmallCap 600 on November 17, 2026, due to Pacira's pending acquisition by Viatris for $1.65 billion. Ingram Micro reported Q3 net sales of $15.2 billion, up 20.8% YoY, and net income of $131.1 million, up 31.8%.

Viatris and Innovata seek to appeal a court ruling that invalidated their contracts to supply HIV drugs to South Africa, worth R1.67bn and R1.575bn respectively. The court found their manufacturing licenses had expired during the bidding process. Both companies argue their disqualification was unjustified due to pending license renewals and valid import licenses.

Viatris reported Q3 2026 revenue of $3.75 billion, missing estimates by 1.3%, but beat EPS and EBITDA expectations. The company raised full-year guidance for revenue, EPS, and EBITDA. Growth was driven by higher-margin products and new launches, while supply chain issues impacted some regions. The pending acquisition of Pacira BioSciences is expected to enhance EBITDA and expand product offerings.

Viatris (VTRS) reported Q3 revenue of $3.75B, adjusted EBITDA of $1.2B, and adjusted EPS of $0.71. The company raised 2026 guidance, expecting 2% revenue growth, 6% EBITDA growth, and 8% EPS growth. North American sales rose 7%, driven by complex generics. The company also discussed supply constraints, China policy pressure, and the potential benefits of its Pacira acquisition.